‘Smart’ Nanoparticles Deliver mRNA Directly to Tumors in New Cancer Therapy

Targeted mRNA delivery to cancer cells becomes more precise, reducing off-target side effects in patients.

Researchers at the University of Adelaide have developed "smart" nanoparticles capable of delivering mRNA directly to tumor-associated macrophages, reprogramming them to aid in cancer immunotherapy. These nanoparticles are engineered with antibodies that specifically target TREM2 proteins on these immunosuppressive macrophages. Upon delivery, the mRNA instructs the macrophages to produce CXCL9, a chemical signal that recruits cancer-fighting T cells, and the nanoparticles also carry resiquimod to further stimulate immune pathways. In laboratory tests, this significantly increased CXCL9 production and the expression of immune-activating markers like NOS2 by 89.5 times, while reducing immunosuppressive signals. When tested in mice with aggressive breast cancer, the therapy slowed tumor growth, increased CXCL9 concentration fourfold, and reduced immunosuppressive macrophages by 63 percent. While not enhancing the effect of existing immunotherapies in mice, the treatment induced beneficial immune system changes suggesting potential for lasting responses, with no observed negative side effects in other organs.

This breakthrough in nanoparticle engineering for mRNA delivery addresses a critical challenge in cancer immunotherapy: overcoming the immunosuppressive tumor microenvironment. By specifically reprogramming tumor-associated macrophages, the therapy aims to convert the tumor's defenses into an anti-cancer front, enhancing the efficacy of T cell recruitment and activity. The use of "smart" nanoparticles with antibody targeting demonstrates a significant advancement in precision medicine, ensuring therapeutic agents reach their intended cellular targets with minimal systemic exposure. This opens avenues for more potent and safer immunotherapies, particularly for aggressive cancers where the tumor environment often negates treatment benefits.

The success of this targeted approach signals a maturation of mRNA technology beyond vaccine applications into complex therapeutic interventions. It suggests a future where engineered nanoparticles can serve as sophisticated drug delivery systems, capable of orchestrating intricate cellular reprogramming within the body. The research highlights the potential for combination therapies where targeted delivery systems enhance the effectiveness of existing treatments, and paves the way for developing novel immunotherapies with improved safety profiles by minimizing off-target immune activation. Further development could lead to more personalized and effective cancer treatments.